Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, filed on Thursday with the SEC to raise up to $50 million in an initial public offering.
The Jerusalem, Israel-based company was founded in 2009 and plans to list on the Nasdaq under the symbol ENTX. Entera Bio filed confidentially on July 14, 2017. Oppenheimer & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.
